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Abstract
Wilms’ tumour (WT) is a pediatric tumor of the kidney that arises via failure of the fetal developmental program. The
absence of identifiable mutations in the majority of WTs suggests the frequent involvement of epigenetic aberrations in WT.
We therefore conducted a genome-wide analysis of promoter hypermethylation in WTs and identified hypermethylation at
chromosome 5q31 spanning 800 kilobases (kb) and more than 50 genes. The methylated genes all belong to a-, b-, and c-
protocadherin (PCDH) gene clusters (Human Genome Organization nomenclature PCDHA@, PCDHB@, and PCDHG@,
respectively). This demonstrates that long-range epigenetic silencing (LRES) occurs in developmental tumors as well as in
adult tumors. Bisulfite polymerase chain reaction analysis showed that PCDH hypermethylation is a frequent event found in
all Wilms’ tumor subtypes. Hypermethylation is concordant with reduced PCDH expression in tumors. WT precursor lesions
showed no PCDH hypermethylation, suggesting that de novo PCDH hypermethylation occurs during malignant progression.
Discrete boundaries of the PCDH domain are delimited by abrupt changes in histone modifications; unmethylated genes
flanking the LRES are associated with permissive marks which are absent from methylated genes within the domain.
Silenced genes are marked with non-permissive histone 3 lysine 9 dimethylation. Expression analysis of embryonic murine
kidney and differentiating rat metanephric mesenchymal cells demonstrates that Pcdh expression is developmentally
regulated and that Pcdhg@ genes are expressed in blastemal cells. Importantly, we show that PCDHs negatively regulate
canonical Wnt signalling, as short-interfering RNA–induced reduction of PCDHG@ encoded proteins leads to elevated b-
catenin protein, increased b-catenin/T-cell factor (TCF) reporter activity, and induction of Wnt target genes. Conversely,
over-expression of PCDHs suppresses b-catenin/TCF-reporter activity and also inhibits colony formation and growth of
cancer cells in soft agar. Thus PCDHs are candidate tumor suppressors that modulate regulatory pathways critical in
development and disease, such as canonical Wnt signaling.
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Introduction
Wilms’ tumour (WT) represents a paradigm for cancer arising
from disrupted development. Failure of the metanephric blaste-
mal cells to undergo mesenchymal to epithelial transition,
together with proliferation of these undifferentiated cells, is
intrinsic to the development of Wilms’ tumours [1]. Thus WT
predisposing genes are often critical in normal nephrogenesis. As
the aetiology of WTs cannot be explained solely by the known
genetic changes, we have evaluated epigenetic changes in WTs.
Several epigenetic lesions have previously been identified in
Wilms’ tumour, in particular loss of imprinting at chromosome
11p13 [2,3] and 11p15 [4], which we have shown to be early and
independent events [5]. In common with other cancers, WTs also
show tumour suppressor gene silencing which includes genes such
as HACE1 (73% of tumours analysed) [6], RASSF1 (56%) [7],
CASP8 (43%), MGMT (30%), RASSF5/NORE1 (15%), and
CDKN2A (10–15%) [8]. In addition, we have recently shown
over-expression of the GLIPR1 gene resulting from promoter
hypomethylation (87%) [9].
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tumorigenesis, we undertook genome-wide analysis of promoter
methylation. We have identified pronounced tumour-specific
hypermethylation in a region spanning ,800 kb of chromosome
5q31. This region contains members of the PCDH superfamily in 3
multi-gene clusters (PCDHA@, PCDHB@ and PCDHG@) [10].
Hypermethylation of this locus is an example of long range
epigenetic silencing, which has previously been reported in
colorectal cancer at chromosome 2q14.2 [11], the MLH1 locus
on 3p22 [12], and for the HOXA gene cluster on chromosome
7p15 in breast and lung cancers [13,14]. We demonstrate that
silencing of gene expression is concomitant with DNA hyper-
methylation and repressive histone modifications. Although little is
known about the functions of these clustered PCDHs, other
members of the PCDH superfamily have been shown to have
tumour suppressor activity, such as PCDH10 in various
carcinomas [15,16] and PCDH8 in breast cancer [17]. Functional
data presented here suggest that proteins encoded by the
chromosome 5q31 PCDHs modulate the Wnt pathway and are
candidate Wilms’ tumour suppressor genes.
Results
A large hypermethylated domain at 5q31 in Wilms’
tumour
Following methylated DNA immunoprecipitation (MeDIP,
Figure S1A), the efficacy and specificity of the MeDIP protocol
was verified using quantitative real-time polymerase chain reaction
(PCR) of a constitutively methylated CpG island (CGI) at the H19
imprinting control region, demonstrating successful enrichment
relative to input DNA. Specificity for methylated CGIs was shown
by PCR of the RASSF1 59 CGI. Amplification of a non-CGI
sequence (an intragenic region of the TBP gene), was used as a
negative control for methylated DNA enrichment (Figure S1B).
Validated MeDIP DNA samples from human fetal kidney and
Wilms’ tumours were then hybridised to Nimblegen HG18 Refseq
promoter microarrays (MeDIP-chip) to detect tumour-specific
alterations in methylation.
Microarray data from 5 sporadic WTs were examined to
identify promoters displaying tumour-specific hypermethylation
(P,0.05, t-test). Overall we found 2043 hypermethylated genes.
Significantly, a large subset of these targets were found in 2 or
more tumours; pairwise comparisons showed that each individual
tumour had between 12.0% and 33.7% (mean 23.8%) of
hypermethylated targets in common with the other tumours
analysed. The genomic distribution of recurrently hypermethy-
lated genes was non-random (P,0.001, chi square test), with many
being located together or within gene clusters (Table S1).
Contiguous hypermethylated genes were more likely to be found
in several tumours (13 out of 17 loci).
Strikingly, of 146 annotated genes hypermethylated in 3 or
more tumours, 25 were PCDHs located at chromosome 5q31 and
MeDIP-chip data revealed enriched tumour/normal ratios
across 50 closely-linked CGIs spanning 800 kb on chromosome
5q31.3 (Figure 1A and Figure S1C). Hypermethylation at this
locus was identified in all tumours examined (Table S2) and
hypermethylated CGIs localise to PCDHA@, PCDHB@ and
PCDHG@.Ea c hPCDHB@ gene is encoded by a single, unspliced
exon, while the PCDHA@ and PCDHG@ genes have unique 59
exons splicing into cluster-specific constant region exons
encoding invariant cytoplasmic domains [10]. Proximal and
distal boundaries to the hypermethylated domain were apparent
(Figure 1A) and, remarkably, tumour MeDIP signal was enriched
at virtually all of the PCDH CGIs across the locus (Figure 1B). As
a complementary screening approach, we also conducted
enrichment of methylated DNA from the WiT49 Wilms’ tumour
cell-line [18] using recombinant methyl-CpG binding domain
(MBD) protein, which permitted microarray methylation profil-
ing without probe DNA amplification. This analysis also showed
hypermethylation of multiple PCDHs across the region (data not
shown). Both genome-wide analyses identified genes previously
known to be hypermethylated in Wilms’ tumour, such as RASSF1
(Table S2). Thus our genome-wide promoter analysis identifies a
novel region of long-range epigenetic silencing in WTs on
chromosome 5q31.3.
Long-range epigenetic modifications at 5q31 are
common in Wilms’ tumour but not in preneoplastic
lesions
We used combined bisulfite and restriction analysis (COBRA) to
validate and characterise methylation in normal and tumour
DNAs. Methylation profiles were consistent with the microarray
data, and locus-wide hypermethylation was observed in all
tumours and WiT49 cells (Figure 1C and 1D). We also analysed
an additional thirteen PCDHs that were identified as hypermethy-
lated by MeDIP-chip, demonstrating that hypermethylation varied
between individual tumours (Figure 1C and 1D). Of 19 PCDHG@
genes, 15 were hypermethylated according to COBRA and array
analysis, together with 15/16 PCDHB@ genes and 13/15
PCDHA@ genes. Bisulfite sequencing data was consistent with
COBRA and MeDIP-chip data (Figure 1E). In total, we analysed
38 WTs (Table S2) and all display hypermethylation of multiple
PCDHs, with many PCDHs showing a very high frequency of
hypermethylation in tumours. These include PCDHGA3, hyper-
methylated in 24/27 tumours (89%), PCDHGB4 (23/25, 92%),
PCDHGA2 (11/13, 85%) and PCDHB3 (21/33, 64%). COBRA
analyses of PCDHAC1, PCDHAC2, PCDHB1, PCDHGC3 and
PCDHGC4 showed no evidence of hypermethylation, consistent
with MeDIP-chip data (Figure 1B and 1C and Table S2).
Analysis of PCDH methylation in microdissected perilobar
nephrogenic rests, presumptive WT precursor lesions, revealed no
PCDH hypermethylation (Figure S3) but hypermethylation was
evident at the PCDHGA3 and PCDHGB4 genes in a set of stromal-
predominant tumours (Figure S4). Taken together our data show
that hypermethylation occurs at high frequencies in all WT
subtypes, and strongly suggests that de novo methylation arises
Author Summary
The development of tissues and organs in the human body
requires carefully regulated production of proteins by cells.
Proteins permit the growth and development of the many
varied structures required for a healthy body. In many
diseases, including some cancers, tissues and organs fail to
develop as they should due to the normal production of
proteins being changed. The work presented here shows
that in Wilms’ tumor, a childhood cancer of the kidney, a
large group of related proteins that are likely necessary for
growth and development of a normal kidney are not
produced properly. This is due to their production being
switched off within the cancer cells. We show how these
proteins, known as protocadherins, can themselves alter
the function of other proteins already known to be
important in normal growth and cancer. Thus our study
increases our understanding of how protocadherins are
important in normal growth and of how altering proto-
cadherins may lead to disease, such as cancer.
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tumour.
There was no tumour-specific hypermethylation apparent at
upstream and downstream CGIs within 100 kb (eight promoter
CGIs in total) of the PCDH clusters. A non-clustered proto-
cadherin gene on chromosome 5q31, PCDH1, 300 kb telomeric to
PCDHG@, was also unmethylated. Two non-PCDH genes are
situated within the methylated domain; SLC25A2 was constitu-
tively methylated in both normal tissues and tumours and TAF7
was constitutively unmethylated (Figure 1C and Figure S2). Thus,
their methylation is unaffected by the surrounding epigenetic
defect, and tumour-specific hypermethylation is specific to
clustered PCDHs.
Silencing of PCDH expression in Wilms’ tumour
Quantitative RT-PCR showed negligible PCDHA@ expression
in kidney. However, PCDHB@ and PCDHG@ transcripts were
readily detectable in fetal kidney, and consistent suppression of
methylated PCDHG@ transcripts was apparent in tumours relative
to kidney. Of 11 hypermethylated PCDHG@ genes analysed in our
tumour panel, 9 showed greater than 90% repression, with the
remaining 2 showing very low basal expression in fetal kidney. For
many PCDHs, expression in tumours was decreased over 100-fold
or below the limits of detection (Figure 2A). PCDHGC3 was
consistently unmethylated in WTs (Figure 1C), but PCDHGC3
expression was lowered in WTs relative to normal kidney
(Figure 2C). Interestingly, WiT49 PCDH methylation and
expression reflects the general silencing pattern observed with
WTs (Figure 2B), but in addition to PCDHGC3, PCDHGA6 is also
unmethylated in WiT49 cells. Despite the absence of hypermethy-
lation, reduced expression of both PCDHGA6 and PCDHGC3
transcripts relative to fetal kidney was apparent in Wit49 cells.
Expression of PCDHGA6 was, however, further suppressed in WTs
with PCDHGA6 hypermethylation (Figure 2C).
Figure 1. A large hypermethylated domain on chromosome 5q31 in Wilms’ tumour. (A) The MeDIP-chip tumour/normal (T/N) signal ratio
shown for 2 representative WTs identifies hypermethylation of multiple gene promoters across a domain spanning 800 kb on chromosome 5q31.3
(red box). (B) The MeDIP-chip profile of PCDHA@, PCDHB@ and PCDHG@ in a representative WT. A minority of genes escaping hypermethylation are
indicated (black arrowheads). (C) DNA methylation assayed using COBRA. Percentage methylation was analysed by gel densitometry for each gene,
and is represented by horizontal bars (black = percentage methylated, white = percentage unmethylated). Data from 6 normal tissues (4 fetal
kidneys [FK], postnatal kidney [NK] and fetal brain [FB]) and 9 Wilms’ tumours are shown. Non-PCDH genes flanking the domain and between
PCDHB@ and PCDHG@ are also shown. (D) Unsupervised hierarchical clustering of COBRA methylation data from normal and tumour tissues (T),
HEK293 and WiT49 cell lines. (E) Bisulfite sequencing of PCDHB3, PCDHB8, SLC25A2, PCDHGA3, PCDHGA6 and PCDHGB4 59 CGIs in normal fetal kidney
(FK) and 2 Wilms’ tumours, T43 & T57.
doi:10.1371/journal.pgen.1000745.g001
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than the PCDHG@ genes. PCDHB8 and PCDHB15 exhibited
strong methylation associated silencing but PCDHB12 was not
consistently down-regulated in tumours, despite hypermethylation
(Figure 2A). All seven methylated PCDHB@ genes analysed were,
however, concordantly silenced in WiT49 cells (Figure 2B).
Unmethylated genes outside the LRES boundary, such as HARS2
and HDAC3, were not suppressed (Figure 2A and 2C).
To further establish the relationship between methylation and
expression, we treated WiT49 cells with 5-azacytidine, which
induced the expression of epigenetically silenced PCDHB@ and
PCDHG@ genes (Figure S5); in contrast, genes located outside the
hypermethylated domain, which showed unaltered expression in
tumours (Figure 2), were unaffected by 5-azacytidine. This
substantiates the mechanistic link between methylation levels
and gene expression at this locus.
In summary, our expression analyses demonstrate that
PCDHB@ and PCDHG@ expression occurs in human kidney,
and that epigenetic silencing of gene expression occurs in WT.
Profiling of histone modifications at active and silenced
genes within the 5q31 LRES
We compared permissive (histone 3 dimethyl lysine 4,
H3K4me2; histone 3 acetyl lysine, H3Ac) and repressive (histone
3 dimethyl lysine 9, H3K9me2) histone modifications at gene loci
across the PCDH domain (Figure 3) by chromatin immunopre-
cipitation analysis (ChIP). Genes located outside the PCDH
domain were enriched for H3K4me2 and H3Ac. Conversely,
methylated PCDHs were enriched for H3K9me2. Hypermethy-
lated PCDHA@, PCDHB@ and PCDHG@ genes all showed
repressive histone modifications. As expected, the SLC25A2
(constitutively methylated) and TAF7 (unmethylated) genes were
associated with repressive and permissive modifications, respec-
tively. The PCDHB6, PCDHGA6 and PCDHGC3 genes, which
were not hypermethylated in the WiT49 cell line, all had an active
chromatin profile.
Comparison of gene expression levels, DNA methylation and
histone marks (Figure 3, right panels) shows that DNA hypermethy-
lation and silencing correlate with diminished H3Ac and
Figure 2. Silencing of PCDH expression in Wilms’ tumour. (A) Expression levels of genes across the locus in 9 tumours (Texp), relative to the
mean of 4 normal fetal kidney samples (N exp). Grey bars are used for genes showing tumour-specific hypermethylation, white bars for unmethylated
genes and black bars for the constitutively methylated SLC25A2 gene. (B) Expression levels of 5q31 transcripts correspond with DNA methylation
status in WiT49 cells. Expression of unmethylated genes (white bars), constitutively methylated genes (black bar) and hypermethylated PCDHs (grey
bars) are shown. (C) Suppression of methylated and unmethylated PCDHs within the chromosome 5q31 LRES. Gene expression levels relative to the
house-keeping gene TBP are shown. Horizontal black line, median value; box, interquartile range; whiskers, data range excluding outliers; black dots,
outliers (defined as those data points greater than range multiplied by inter-quartile range beyond the box). Grey boxes give samples shown to be
hypermethylated, open boxes represent unmethylated samples.
doi:10.1371/journal.pgen.1000745.g002
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H3K4me2 levels (Spearman rank order correlation coefficient,
r=0.67, P=0.003, and r=0.63, P=0.006 respectively). H3K9me2
shows an opposite pattern, that is high levels at methylated/silenced
genes (Spearman rank order correlation coefficient, r=20.83,
P=0.0002). The degree of H3K9me2 enrichment displays
proportionality to gene silencing (Pearson correlation coefficient,
r=0.88). Thus tumour-specific DNA hypermethylation is strongly
linked with specific, repressive chromatin modifications, whereas
unmethylated genes within, and flanking the region maintain an
active chromatin configuration.
PCDH expression in renal development and
differentiation
Previous studies have indicated that PCDH expression is largely
restricted to neuronal tissues [10]. As we found abundant
expression of PCDHB@ and PCDHG@ genes in human fetal
kidney (Figure 2), we examined Pcdhb@ and Pcdhg@ expression
during murine kidney development. Similar to humans, Pcdha@
genes were expressed predominantly in brain, with negligible
levels in kidney. In contrast, Pcdhb@ and Pcdhg@ expression was
abundant in kidney, with expression comparable to brain and
exceeding placenta, liver and spleen. Transcript levels followed
similar temporal profiles to Wt1, a mediator of mesenchymal-
epithelial transition (Figure 4A). Postnatally, Pcdh expression
decreases, in contrast to E-cadherin (Cdh1), where high expression
levels are maintained in the mature organ. As our human
expression analysis was restricted to comparing transcript levels in
fetal kidney and Wilms’ tumours (Figure 2), we also assessed other
human fetal tissues for PCDHG@ encoded proteins by immuno-
blotting in order to confirm abundant expression in fetal kidney.
High expression was also evident in lung and brain, compared
with moderate expression in gut. On longer exposure, low
expression was also apparent in liver and spleen (Figure 4B).
In order to gain further insight on cell-type specific expression,
we analysed Pcdhb@ and Pcdhg@ transcript levels during epithelial
differentiation of rat metanephric mesenchymal cells in organ
culture. This system has been shown to accurately reflect early
differentiation in embryonic kidney [19]. Freshly isolated meta-
nephric mesenchymal cells were found to express high Pcdh levels,
and epithelial differentiation induced by growth factors was
accompanied by down-regulation of Pcdhga6, Pcdhga12 and Wt1.
Pcdhga2 and Pcdhgc3 were also decreased upon differentiation,
but to a lesser extent (Figure 4C). As expected, a sharp rise
in Cdh1 expression was observed, consistent with increasing
epithelialisation.
Figure 3. Hypermethylation across the chromosome 5q31 LRES is associated with specific histone modifications. Bar charts (left) show
ChIP–quantitative PCR measuring relative levels of specific histone modifications at individual gene loci across the 5q31 locus in WiT49 cells. (A) H3Ac
ChIP, (B) H3K4me2 ChIP, (C) H3K9me2 ChIP, all expressed relative to input DNA. Scatter plots (right) show the relationship between relative gene
expression levels and histone modifications at each gene. The x-axis shows specific histone levels relative to input DNA, and the y-axis shows mRNA
expression in WiT49 cells (Texp) relative to average mRNA expression in 4 fetal kidney samples (Nexp). Grey bars/datapoints signify genes
hypermethylated in WiT49, open bars/datapoints show unmethylated genes, and the black bar/datapoint shows constitutively methylated SLC25A2.
doi:10.1371/journal.pgen.1000745.g003
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PLoS Genetics | www.plosgenetics.org 5 November 2009 | Volume 5 | Issue 11 | e1000745Figure 4. Developmental expression patterns of PCDHs. (A) PCDH transcript levels in mouse developmental tissues. Quantitative real-time
expression analysis, relative to Tbp, in placenta (P), and E17.5 mouse fetal liver (Li), spleen (S), brain (B), and kidney (K) (E17.5, postnatal 0.5 week, 1
week, and 3 week) using assays specific for the constant region exons of Pcdha@ and Pcdhg@, and individual Pcdh transcripts. Expression of Wt1 and
Cdh1 are also shown (black bars). (B) Immunoblotting of human fetal tissue proteins with pan c-PCDH antibody or actin for loading control. Samples
are kidney (K), liver (Li), lung (Lu), spleen (S), brain (B), and gut (G). (C) Gene expression changes accompanying epithelial differentiation of rat
metanephric mesenchyme following Lif, Fgf2, and Tgfa treatment. Quantitative real-time expression analysis, relative to Tbp, is shown for freshly
dissected rat metanephric mesenchyme (MM) and differentiating mesenchyme (DM). (D) Immunohistochemical analysis of 1-day postnatal murine
kidney with antibodies towards Wt1 and c-PCDHs. Blastema (b), primitive glomeruli (pg), and ureteric buds (u) are labelled. The control panel shows a
section where the primary antibody has been omitted. Bar =50 mm.
doi:10.1371/journal.pgen.1000745.g004
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samples and rat mesenchymal cells suggests that the mesenchyme
may be the principal cellular component expressing PCDHs in
developing kidney. We therefore assessed expression of Pcdhg@
encoded proteins (c-PCDHs) immunohistochemically in postnatal
day 1 murine kidney (Figure 4D). High expression was evident in
the blastemal cells, with decreasing and more variable expression
apparent in tubules and parietal epithelia. Subcellular staining was
variable and included nuclear staining, which is consistent with a
role for the c-PCDH intracellular domain in gene regulation
[20,21]. Expression in the ureteric bud and visceral epithelia was
low or absent. Thus c-PCDHs proteins are evident in the murine
equivalent of the presumptive multipotent cell of origin for WT.
This is consistent with PCDHs having a role in kidney
development and Wilms’ tumorigenesis.
Modulation of canonical Wnt signalling by PCDHs
Little is known about PCDH cellular functions, but a member of
the PCDH superfamily, PCDH-PC, was previously shown to
positively regulate b-catenin/TCF signalling [22]. The Wnt
signalling pathway, which utilises the b-catenin/TCF transcrip-
tional complex to programme developmental gene expression, is
essential for nephrogenesis [23]. Constitutive Wnt signalling
brought about by compromised b-catenin function is also involved
in several cancers including WT [24]. We therefore assessed the
possible effects of c-PCDH knockdown on b-catenin/TCF
mediated transcription using luciferase reporter plasmids which
contain a minimal promoter adjacent to 7 tandem TCF binding
sites (Super8xTOPFLASH, [25]). Short-interfering RNAs (siR-
NAs) were designed to target the constant region sequences of
PCDHG@ and transfected into WiT49 cells. Although WiT49 cells
show extensive hypermethylation across the PCDH locus, specific
PCDHs (for example, PCDHGA6 and PCDHGC3) escape hyper-
methylation and are expressed, albeit at lower levels relative to
fetal kidney (Figure 2C); WiT49 cells also exhibit intermediate
Wnt signalling activity in the absence of b-catenin mutations, and
are therefore suitable for investigating PCDH effects on the Wnt
pathway.
The activity of the b-catenin/TCF reporter was increased by
knockdown of c-PCDHs, suggesting that c-PCDHs negatively
influence the canonical Wnt pathway. A second siRNA targeting a
different sequence within the PCDHG@ constant region gave
similar results, negating the possibility of off-target effects (data not
shown). Reporter upregulation was abolished by CTNNB1 siRNA
co-transfection, demonstrating that enhanced TCF-mediated
activation was b-catenin-dependent (Figure 5A). This was further
supported by immunoblot analysis which showed that knockdown
of c-PCDHs was accompanied by elevated b-catenin protein levels
(Figure 5A, inset), although CTNNB1 transcript levels were
unchanged (data not shown). Knockdown of c-PCDHs also
induced expression of known b-catenin/TCF target genes CCND1,
CMYC and PAX8, as well as repressing transcription of WT1
(Figure 5B). We also individually over-expressed PCDHGA2,
PCDHGA6 and PCDHGA12 in WiT49 cells, human embryonic
kidney 293 cells (HEK293) treated with Wnt3a conditioned media
and HCT116 cells to evaluate effects on b-catenin/TCF reporter
activity (Figure 5C). The latter cell-line is derived from a colorectal
cancer with an activating b-catenin mutation [26,27] and also
displays PCDH hypermethylation (Figure S6). PCDH-mediated
suppression of b-catenin/TCF reporter activity was evident in all
cell-lines, especially Wnt3a-treated HEK293 and HCT116, both
of which have high Wnt signalling. As expected, expression of a
dominant-negative form of TCF4 also strongly reduced reporter
activity. Taken together, our data implicate PCDHG@ encoded
proteins in negative modulation of canonical Wnt signalling.
As our epigenetic and functional analyses allude to a tumour
suppressor function for PCDHs, we evaluated the effect of ectopic
PCDH expression on tumour-related phenotype using cell-culture
based assays commonly used for assessing tumour suppressor gene
function, that is inhibition of colony formation and growth in soft
agar [15]. Transfection of WiT49 cells with PCDHGA2, PCDHGA6
or PCDHGA12 resulted in moderate PCDH protein expression
leading to approximately 30–85% suppression of colony formation
Figure 5. PCDH effects on Wnt signalling. (A) Enhanced b-catenin/
TCF activity following c-PCDH knockdown induced by PCDHG@
constant region targeting siRNA, measured with Super8xTOPFLASH
reporter (TOP). Super8xFOPFLASH (FOP) reporter is a negative control.
RLU, relative luciferase units. Gamma-PCDH and b-catenin knockdowns
are verified by immunoblotting (IB) in the inset, which also
demonstrates increased cellular b-catenin accompanying c-PCDH
knockdown. (B) Quantitative real-time expression analysis, relative to
TBP, showing induction of the Wnt pathway target genes CCND1, CMYC,
and PAX8 accompanying c-PCDH knockdown; altered expression of
WT1 is also shown. (C) Repression of b-catenin/TCF reporter activity
accompanying PCDH expression in WiT49, HCT116, and Wnt3a-
conditioned medium treated HEK293 (HEK293+CM) cells. A plasmid
containing a cDNA encoding dominant-negative TCF4 (TCF4-DN) is also
shown as a positive control. Cells were co-transfected with PCDH
expression vectors and Super8xTOPFLASH (TOP) or Super8xFOPFLASH
(FOP) and luciferase activity measured. RLU, relative luciferase units.
doi:10.1371/journal.pgen.1000745.g005
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cells resulted in approximately 70% suppression of colony
formation (P,0.01), and transfection of HEK293 cells led to
60–85% suppression (P,0.005) (Figure 6A). Suppression of colony
formation was not a non-specific side-effect of gene over-
expression, as transfection of HEK293 cells with CTNNB1 cDNA
encoding a degradation-resistant mutant of b-catenin failed to
suppress colony formation (Figure S7).
We also assessed the effect of PCDH expression on anchorage
independent growth in soft agar using HCT116 cells (Figure 6B).
Colony forming efficiency was markedly reduced by PCDHGA2,
PCDHGA6 and PCDHGA12 relative to cells transfected with
expression vector only (approximately 85%–95% suppression
relative to the vector control).
Collectively, therefore, our experiments demonstrate that
PCDHs regulate critical transduction and transcription pathways
and have growth regulatory properties consistent with tumour
suppressor activity.
Discussion
By conducting genome-wide promoter methylation analysis, we
have identified a large cluster of paralogous PCDH genes on
chromosome 5q31 which undergo hypermethylation in Wilms’
tumours. Transcriptional silencing of PCDHs was prevalent in WTs,
and PCDH hypermethylation constitutes the most frequent epige-
netic silencing event in WT. This putative WT suppressor domain is
thefirstreportofLRESinchildhoodtumours.Ourdataalsosuggests
roles for PCDHs in normal nephrogenesis, including modulation of
key regulatory pathways such as canonical Wnt signalling.
LRES regions have been identified in several adult cancers
including, breast [13], colon [11,12], head, neck and lung
[14,28,29]. A recent genome-wide analysis of methylation in
breast cancers showed that multiple agglomerative epigenetic
aberrations occur, including regions undergoing hypermethylation
and hypomethylation. Interestingly, the PCDH locus on chromo-
some 5q31 was one of several hypermethylated domains shown in
breast cancer, together with others such as HOXD@ on
chromosome 2 and HIST1 on chromosome 6 [30]. Such regions
were also identified in our analysis (Table S1). Thus, in addition to
gene-specific epigenetic lesions, our study shows that some, but not
all, LRES domains are conserved between embryonal and adult
cancers. Also individual genes within an LRES region can show
tumour-type specific changes, illustrated by PCDHGC3 which is
frequently hypermethylated in breast cancer but which escapes
methylation in WTs. The contribution of LRES to tumour
pathology is not well characterised, but transcriptional suppression
of multiple genes across a chromosomal region can be considered
to be functionally analogous to cytogenetic loss.
Silencing of individual genes within the LRES domains on
chromosome 2q and 3p in colorectal cancer appears to be
dependent on a domain-wide non-permissive chromatin configu-
ration, rather than the methylation status, as unmethylated genes
within these domains and up to 1000 kb away are also suppressed
Figure 6. Growth inhibition by PCDHs. (A) Suppression of WiT49, HCT116, and HEK293 cell colony formation following ectopic expression of
PCDH cDNAs. After selection and staining, plates were photographed and colony counts determined for each transfection. Representative plates (left)
and mean colony counts (right) are shown, Verification of PCDH protein expression after transfection, together with tubulin as a loading control is
shown below the histograms. (B) Inhibition of anchorage-independent growth of HCT116 cells by PCDHs, cells were plated in triplicate and colonies
formed after 10–14 days were photographed and counted within 10 random fields. Representative fields are shown (left) together with colony
forming efficiency (CFE), expressed as percentage of colonies .50 mm diameter (right). Cell-based assays were repeated at least twice, and
representative data are shown.
doi:10.1371/journal.pgen.1000745.g006
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(TAF7 and SLC25A2) was strongly linked to methylation status in
WTs, and the transcriptional status of unmethylated genes
flanking the LRES was unchanged in tumours. A comparatively
lesser degree of transcriptional suppression is observed for the
unmethylated PCDHGC3 and PCDHGA6 genes in WiT49 cells.
This suppression occurs despite any significant changes in active/
repressive histone marks and suggests that PCDHGA6 and
PCDHGC3 are repressed by a non-epigenetic effect such as altered
feedback regulation resulting from lowered levels of c-PCDH
intracellular domain fragments. Similar to the Notch signalling
paradigm, regulated presenilin dependent-processing of the c-
PCDHs generates C-terminal fragments which can localize to the
nucleus and autoregulate the c-PCDHs [20,21].
In contrast to breast cancer [30], our ChIP data shows a strong
link between DNA methylation and H3K9me2 at silenced PCDH
genes, as reported for the LRES on chromosome 2q14.2 and 3p22
[11,12]. Indeed a correlation between degree of silencing and
H3K9me2 enrichment was apparent, whereas H3K4me2 and
H3Ac marking is evident in all active genes and lost in silenced
genes. This suggests that H3K9me2 plays a role in establishing
and maintaining the silenced state, as previously demonstrated for
CDKN2A [31], and that histone 3 acetylation and H3K4me2
marks are removed prior to increases in H3K9me2 and DNA
methylation. It has been postulated that a significant proportion of
hypermethylated loci in cancer do not arise by adaptive selection
but rather are the result of an ‘instructive’ mechanism, via cis-
targeting of the trans-acting Polycomb group protein-complexes
[32], and that these loci are pre-marked in normal (unmethylated)
tissues by histone H3 trimethyl - lysine27 (H3K27me3). The
instructive mechanism may explain the non-random de novo
methylation of some genes during tumorigenesis [33]. However,
in the case of the 5q31 LRES, a genomic study of human
embryonic stem cells failed to identify pre-marking of the
hypermethylated PCDHs by Polycomb group proteins or
H3K27me3 [34]. Additionally, the instructive mechanism predicts
methylation would be present in pre-cancerous lesions (e.g.
colorectal adenomas [32]) and we have shown this is not the case
for PCDHs, which are unmethylated in nephrogenic rests, pre-
cancerous lesions for WT. Therefore the PCDHs do not appear to
be pre-marked for de novo methylation in WT, indicating that this
molecular lesion is selected for during tumorigenesis. This is also
supported by tumour-type specific variations in hypermethylation
such as observed for PCDHGC3, as discussed above.
Hypermethylation of PCDHs was not detectable in nephrogenic
rests, consistent with a previous assessment of RASSF1, DNAJC15/
MCJ and TNFRSF25 gene hypermethylation [35]. This is in
contrast to gene-specific hypomethylation of the GLIPR1 gene
observed in WTs, where nephrogenic rests display intermediate
methylation levels relative to fetal kidney and WTs [9]. Therefore
although the GLIPR1 hypomethylation observed in WTs might
reflect an expansion of oncofetal cells lacking GLIPR1 methylation,
hypermethylation of PCDHs and other tumour suppressor genes
appears to represent a later, tumour-specific lesion. Expression of
PCDHs in blastemal cells, together with our methylation analysis
of nephrogenic rests, also negates the possibility that Wilms’
tumour PCDH hypermethylation can be attributed to clonal
expansion of progenitors with cell-type specific methylation.
Genetic lesions in WT known to be late events include
chromosome 16q loss of heterozygosity [36] and CTNNB1
mutations [37]; interestingly, the CTCF gene locates to 16q, is
mutated in some WTs [38] and the encoded epiregulatory protein
has multiple binding sites across the PCDH locus [39], suggesting
that aberrant CTCF function may be involved in LRES.
Expression of the Pcdhs peaks in the last week of nephrogenesis;
thereafter, expression decreases, in contrast to Cdh1, which
encodes the archetypal epithelial adhesion protein, E-cadherin.
Epithelial differentiation of rat metanephric mesenchyme cells in
organ culture was also accompanied by decreasing levels of
Pcdhg@ expression. A recent microarray analysis of gene
expression with laser captured kidney components showed
expression of Pcdhb15 and Pcdhga12 expression attenuating
between the cap mesenchyme and renal vesicle [40]. Together
with our expression analyses, this suggests that the Pcdh expression
peak in murine nephrogenesis likely reflects the expansion of
nephrogenic progenitors as kidney development nears completion
[41]. Our PCDH expression analyses in human fetal kidney,
during murine nephrogenesis and in rat metanehpric mesenchyme
suggest that PCDHs may have hitherto uncharacterised roles in
renal development. Although Pcdhg@ mutant mice, which undergo
neurodegeneration and neonatal death in less than 12 hours, did
not show a gross kidney phenotype, kidney defects were not
explored in detail [42] (Wang & Sanes, personal communication).
The early postnatal lethality observed with homozygous Pcdhg@
mutant mice would also preclude full assessment of effects on
nephrogenesis, as murine kidney development continues in the
first week following birth. Although we were unable to assess renal
defects in Pcdhg@ null mice, we did examine postnatal kidney from
heterozygous Pcdhg@ mutant mice (see Text S1), as heterozygous
mutations of developmental genes such as Wt1 have been shown to
result in end-stage renal disease [43]. Histological examination of
kidneys from 3 month old heterozygotes showed no evidence of
overt kidney malformations (Figure S8). However, it will clearly be
of great interest to analyse a larger heterozygous cohort together
with embryonic kidney from homozygous Pcdhg@ mutants in
future studies.
The canonical Wnt signalling pathway is a prerequisite for
initiating and maintaining mesenchymal to epithelial transitions
during kidney development, and it is also known that mesenchyme
with high b-catenin activity fails to form epithelial structures [44].
Thus attenuation of Wnt signalling is necessary during nephro-
genesis. Importantly, our functional analysis shows that c-PCDHs
repress b-catenin/TCF mediated transcription, with lowered
PCDH leading to elevated b-catenin protein, high b-catenin/
TCF reporter activity and induced expression of Wnt target genes.
Conversely, ectopic expression of PCDHs was able to suppress b-
catenin/TCF reporter activity in heterologous cell systems. In
contrast to Wnt target genes, WT1 expression levels were reduced
by PCDH knockdown, demonstrating that Wnt target gene
induction is not reflecting a generalised increase in transcription
and that other regulatory networks are also influenced by cellular
PCDH levels. The significance of these results is underlined by our
findings of epigenetic silencing of PCDHs in WT, as this would be
predicted to lead to elevated b-catenin/TCF activity. In this
regard, it is notable that enhanced b-catenin signalling in WTs is
observed more frequently than CTNNB1 and WTX mutations in
WTs [45,46] and that CTNNB1 mutation is, like PCDH silencing, a
late event in Wilms’ tumorigenesis. Although our analysis of
PCDHs on Wnt signalling can only approximate the permuta-
tional silencing in WTs, our results prompt the hypothesis that the
canonical Wnt pathway is modulated by PCDHs, and that in
normal nephrogenesis, elevated PCDHs serve to downregulate b-
catenin activity, thereby permitting completion of epithelial
differentiation. Epigenetic silencing of PCDHs might contribute
to deregulation of Wnt signalling, and a failure of mesenchymal to
epithelial transition resulting in persistence of a progenitor cell
pool and consequent Wilms’ tumorigenesis. PCDHs may also have
a role in the aetiology of other cancers, such as breast cancer,
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Wnt/b-catenin signalling occurs, despite mutations of Wnt
pathway components being rare [47].
Although the mechanisms by which PCDHs influence pathways
such as Wnt signalling require delineation, we note that, as well as
encoding a nuclear moiety capable of regulating gene expression
directly [20,21], a- and c-PCDHs have recently been reported to
negatively regulate proline-rich tyrosine kinase 2 (PYK2) [48]
which was previously shown to phosphorylate b-catenin [49]. As
phospho-regulation of b-catenin can promote interactions with
transcriptional co-activators [50], we speculate that elevated
PYK2 activity may arise as a consequence of PCDH silencing
and thereby lead to a shift of the b-catenin adhesion/signalling
balance. This and other downstream consequences of PCDH
silencing warrant intensive future study.
Materials and Methods
Ethical statement
All human tissues were acquired with appropriate local research
ethics committee approval and all animal procedures were
conducted in accordance with regulations (UK Home Office)
and international standards on animal welfare.
Patient samples
All tissues were obtained as snap frozen samples from the Bristol
Children’s Hospital, the Royal Marsden Hospital and the
University of Heidelberg Children’s Hospital. Human fetal tissue
samples were from 19 to 31 weeks of gestation. Details of clinical
samples are given in Table S3.
Cell culture, transfections, and reporter assays
WiT49 [18], HCT116 [9] and HEK293 cell-lines (adenovirus
transformed human embryonic kidney cells [51]) were cultured
using standard methods in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal calf serum, 2 mmol/l L-
glutamine, 0.1 mg/ml penicillin/streptomycin, at 37uC under 5%
CO2. L/Wnt3a fibroblast cell lines (ATCC, Manassas, VA) were
grown in DMEM supplemented with 10% fetal calf serum, and
Wnt3a conditioned medium was prepared according to the
protocol provided by ATCC (http://www.atcc.org).
For knockdown analyses, cells were transfected with Dharma-
FECT DUO (Dharmacon, Inc.) with 50 nM total of ON-
TARGETplus short interfering RNA (siRNA) duplexes. For b-
catenin/TCF reporter activity assays, 10
5 cells/well were seeded in
24-well plates and 100 ng of Super 8xTOPFLASH or Super
8xFOPFLASH reporter plasmids were co-transfected with siRNAs
and 100 pg of pRL-SV40 to normalise for transfection efficiency.
Super 8xFOPFLASH is a negative control for Super 8xTOP-
FLASH containing mutated TCF binding sites [25]. Luciferase
samples were assayed after 48 hours using Dual-luciferase reporter
kit (Promega) and a Modulus Luminometer (Turner Biosystems).
Experiments were performed at least twice in triplicate.
For rat mesenchymal organ culture, dissected fresh metanephric
mesenchyme from E13.5 rat embryos was cultured on collagen
coated transwell filters (Corning) in DMEM/F12 media containing
20 mg/ml penicillin/streptomycin, 10 mg/ml insulin, 10 mg/ml
transferrin, 10 ng/ml selenium (ITS), 40 ng/ml dexamethasone,
100 ng/ml prostaglandin, 4 ng/ml tri-iodo-l-thyronine, 10 ng/ml
holo-transferrin. Epithelial differentiation was induced over 5 days
with 50 ng/ml leukemia inhibitory factor (Lif, Chemicon), 20 ng/
ml transforming growth factor a (Tgfa, R&D Systems) and 50 ng/
ml fibroblast growth factor (Fgf2, R&D Systems) [19], after which
RNA was extracted with Tri reagent (Sigma).
For PCDH over-expression studies, cDNAs were obtained by
RT-PCR from fetal kidney RNA and cloned into pCDNA3.1/Zeo
(Invitrogen). For b-catenin/TCF reporter assays, 10
5 cells/well
were seeded in 24-well plates and transfected with 400 ng of
expression constructs together with 100 ng Super 8xTOPFLASH
or Super 8xFOPFLASH using Fugene 6 (Roche), and assayed for
luciferase as described above. For colony formation assays,
2.5610
5 HCT116 and WiT49 cells were transfected with 1 ug
of expression plasmids in 6-well plates and plated in triplicate in
10 cm dishes 48 hours after transfection. Selection was performed
with 200 mg/ml (HCT116) or 100 mg/ml (WiT49) of zeocin
(Invitrogen) for 2 weeks after which colonies were methylene blue
stained and counted using ImageJ software (http://rsbweb.nih.
gov/ij/). Colony formation assays were repeated at least twice.
Growth in soft agar was assessed essentially as previously
described [15]. Briefly, 2.5610
4 transfected HCT116 cells were
suspended in DMEM medium containing 10% fetal calf serum,
0.35% agar, and 200 mg/ml zeocin. The suspension was then
layered on 6 cm plates containing DMEM medium containing
10% fetal calf serum, 0.7% agar, and 200 mg/ml zeocin. Plating
was carried out in triplicate and repeated at least twice. Cells were
fed every 4–5 days, and after 10–14 days growth, colonies of
greater than approximately 50 mm within 10 microscopic fields
were counted under a phase contrast microscope. Colony forming
efficiency is presented as percentage of colonies larger than 50 mm
within total cells.
Methylated–DNA immunoprecipitation (MeDIP) and
chromatin immunoprecipitation (ChIP)
High molecular weight genomic DNAs were extracted from
tissues using standard phenol-chloroform techniques and fragment-
ed to a size range of 200–500 base pairs using a Diagenode
Bioruptor. Four micrograms of sonicated genomic DNA and 20 mg
anti-5-methyl cytidine monoclonal antibody (Eurogentec, Lie `ge,
Belgium) were incubated at 4uC overnight in immunoprecipitation
buffer, and then for a further 2 hours with goat anti-mouse IgG
magnetic beads (N.E. Biolabs). After purification, MeDIP DNA was
blunt-ended with T4 DNA polymerase (N.E. Biolabs) and ligation-
mediated PCR (LM-PCR) was carried out as described [52,53].
DNAs were then sent to Nimblegen for labelling and hybridization
to Nimblegen HG18 Refseq promoter arrays. Data was analysed
using ChipMonk v1.2.1 tiling array analysis software (Dr Simon
Andrews, Babraham Institute, Cambridge UK, http://www.
bioinformatics.bbsrc.ac.uk/projects/chipmonk). To identify hyper-
methylated CGIs, a log2ratio cut-off of 1.5 and a window of 500 bp
was used to carry out the replicate t-test (P,0.05) on probes within
200 bp of predicted CpG islands (http://genome.ucsc.edu). Addi-
tional statistical analysis was carried out using R (http://www.
r-project.org/). The array data reported in this paper have been
deposited in the Gene Expression Omnibus (GEO) database,
(http://www.ncbi.nlm.nih.gov/geo) under accession number
GSE15027.
WiT49 chromatin marks were assessed using a ChIP Kit
(Upstate Biotechnology) with antibodies for histone 3 dimethyl
lysine 4 (H3K4me2, Upstate Technology), histone 3 dimethyl
lysine 9 (H3K9me2, Abcam), and histone 3 acetyl lysine (H3Ac,
Upstate). Quantification using real-time PCR was carried out
using the Stratagene MX3005P QPCR System (La Jolla, CA)
along with the PlatinumSYBR green qPCR SuperMix-UDG
(Invitrogen). Reactions volumes of 20 ml contained 10 mlo f
Platinum SYBRgreen qPCR SuperMix-UDG (Invitrogen, Paisley,
UK), 50 nM ROX reference dye, 0.2 mM forward primer, 0.2 mM
reverse primer, and 1.5 ml of ChIP DNA template. Primer
sequences are available in Table S4.
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Up to 1 mg DNA was sodium bisulfite converted using the EZ
DNA Methylation-Gold Kit (Zymo Research, CA). Amplicons for
combined bisulfite restriction analysis (COBRA) and bisulfite
sequencing were made using the Hot Start Red Taq PCR system
(Sigma). Primers and restriction enzymes are available in Table
S4. For bisulfite sequencing, PCR products were cloned into the
pGEM-T-easy cloning vector (Promega), and fluorescently
sequenced using standard M13 primer sequences.
For comparative quantitative Real-Time RT-PCR, 1 mgo f
DNAse-treated (TURBO DNA-free, Ambion Inc, TX) total RNA
was reverse-transcribed with oligo(dT)20 at 50uCf o r1h ru s i n gt h e
ThermoScript RT-PCR System (Invitrogen). Real-time PCR was
performed using the Stratagene MX3005P QPCR System (La Jolla,
CA) along with the PlatinumSYBR green qPCR SuperMix-UDG
(Invitrogen).Reactionsvolumesof 20 ml contained10 ml ofPlatinum
SYBRgreen qPCR SuperMix-UDG (Invitrogen, Paisley, UK),
50 nM ROX reference dye, 0.2 mMf o r w a r dp r i m e r ,0 . 2 mM
reverse primer, and 2.5 ml of 1:10 diluted cDNA template. Primer
sequences are available in Table S4. Thermal cycling consisted of an
initial incubation step of 50uC for 2 minutes and a denaturation step
of 95uC for 10 minutes. This was followed by 40 cycles of 95uC/15
seconds, 58uC/30 seconds, 72uC/30 seconds. Gene expression was
quantified by comparative Ct method, normalizing values to the
housekeeping gene TBP. All assays were performed in duplicate.
Immunoblotting and immunohistochemistry
Protein extraction and immunoblotting were carried out
essentially as previously described [2] with primary antibodies to
b-catenin (Cell signalling), a-tubulin (Sigma) and the c-PCDH
constant region (Greg Phillips, Mount Sinai School of Medicine,
USA). This pan c-PCDH antibody is a characterised affinity-
purified rabbit polyclonal against a GST-fusion protein containing
the constant cytoplasmic domain encoded by PCDHG@ [54,55].
This region is highly conserved in human and mouse, with one
amino acid difference in 124 amino-acids. Briefly, tissues were
lysed in 300 ml of sample buffer (60 mM Tris pH 6.8, 10%
glycerol, 2% SDS, 5% mercaptoethanol) and 10 mg protein was
loaded per well and electrophoresed on a 10% SDS –
polyacrylamide gel. After electrophoresis the proteins were
transferred to Immobilon-P (Millipore) with a semidry transfer
apparatus. The Immobilon-P was then transferred to 5% non-fat
dry milk (Tesco) in PBS (milk block) and blocked for a minimum of
1 hour. Primary antibodies were incubated in milk block overnight
at 4uC, followed by the secondary antibody at room temperature
for an hour. Protein bands were visualised with ECL Plus reagents
(Amersham Pharmacia Biotech).
For immunohistochemistry, 5 mm sections of CBA x C57Bl/6
F2 mouse P0 neonatal kidney were fixed for 16 hrs in 4%
paraformaldehyde. Antigen retrieval of deparaffinised sections was
performed by microwaving in 0.8 M urea, pH 6.4, followed by
indirect immunoperoxidase staining using the Elite ABC kit
(Rabbit IgG; Vectastain) according to the manufacturer’s
instructions. Primary antibody dilutions were 1:100 for WT1
(6FH2, Dako), and 1:200 for pan c-PCDH. Sections were
counterstained with haematoxylin. Negative control sections
omitted the primary antibody.
Supporting Information
Figure S1 Analysis of aberrant methylation in Wilms’ tumours
using Nimblegen Refseq promoter HG18 tiling arrays. (A) The
MeDIP-chip workflow used to analyse genome-wide methylation.
Methylated DNA purified from normal and tumour DNAs was
amplified using ligation-mediated PCR (LM-PCR), labelled and
hybridised with promoter microarrays (B) Real-time RT-PCR of
MeDIP-enriched tumour DNAs (upper). Enrichment was validat-
ed using primers specific to a non-CGI sequence within the TBP
gene (grey bars), the constitutively methylated H19 imprinting
control region (black bars), and selective enrichment of the
methylated RASSF1 59-CGI in a methylated and unmethylated
tumour (open bars). MeDIP DNA was quantified relative to input
DNA. The lower panel shows COBRA confirmation of H19
imprinting control region and the RASSF1 59-CGI methylation
status. Arrowheads show methylated (M) and unmethylated (UM)
DNA fragments; presence or absence of restriction enzyme is
indicated (+/2). (C) The tumour (T) versus normal fetal kidney (N)
signal ratio (y-axis) from 17,777 promoter-associated probes are
plotted according to their physical location on chromosome 5 (x-
axis) for 5 WTs. Hypermethylation at 5q31 is indicated by the
vertical arrow.
Found at: doi:10.1371/journal.pgen.1000745.s001 (4.67 MB TIF)
Figure S2 Methylation analysis of genes neighbouring the
chromosome 5q31 PCDH cluster. Arrowheads show methylated
(M) and unmethylated (UM) DNA fragments; presence or absence
of restriction enzyme is indicated (+/2).M+, in vitro methylated
DNA (A) Distal neighbours of the clustered PCDHs in normal and
tumour tissues. COBRA analysis of CD14, TMCO6, NDUFA2 and
WDR55 59-CGIs (located -153, -147, -139, and -119 kbp upstream
of the PCDH clusters, respectively). FK, 22-week fetal kidney;
WTs, five pooled WT DNAs. (B) 59-CGI methylation analysis of
the non-clustered PCDH1 gene (located 366 kbp downstream of
the PCDH clusters) was carried out on eleven WTs using COBRA.
22-week foetal kidney, FK; FK2, 16-week foetal kidney.
Found at: doi:10.1371/journal.pgen.1000745.s002 (1.85 MB TIF)
Figure S3 Methylation analysis of PCDHB6 in WT precursor
lesions. (A) COBRA analysis of PCDHB6 in DNA extracted from
fetal kidney (FK), WTs, and associated perilobar nephrogenic rests
(NR). T, Wilms’ tumours. Arrowheads show methylated (M) and
unmethylated (UM) DNA fragments; presence or absence of
restriction enzyme is indicated (+/2). M+, in vitro methylated
DNA. (B) Bisulfite sequencing analysis. Black circles represent
methylated CpGs and white circles represent unmethylated CpGs.
Found at: doi:10.1371/journal.pgen.1000745.s003 (1.22 MB TIF)
Figure S4 PCDH hypermethylation in stromal-predominant
Wilms’ tumours. COBRA was carried out for PCDHGA3,
PCDHGB4, and HDAC3. Arrowheads show methylated (M) and
unmethylated (UM) DNA fragments; presence or absence of
restriction enzyme is indicated (+/2). M+, in vitro methylated
DNA.
Found at: doi:10.1371/journal.pgen.1000745.s004 (2.02 MB TIF)
Figure S5 Pharmacological demethylation of WiT49 cells.
Quantitative real-time RT-PCR of 5q31 transcripts, mock-treated
(-) or 5-azacytidine treated (+) cells. Grey bars indicate genes
associated with hypermethylated CGIs, white bars represent genes
with CpG islands with no detectable methylation and black bars
are used for SLC25A2. HPRT is an X-chromosome housekeeping
control gene. DIAPH1 and HDAC3 are located on chromosome
5q31 outside the LRES. Expression data for 3 PCDHB@ genes
and 4 PCDHG@ genes is shown relative to TBP, together with
SLC25A2 and TAF7 genes, which are located within the LRES.
Induction of the WT hypermethylated control genes RASSF1 and
H19 is also shown.
Found at: doi:10.1371/journal.pgen.1000745.s005 (2.41 MB TIF)
Figure S6 Hypermethylation of PCDHGA2, PCDHGA6,
PCDHGA12, PCDHB6, PCDHGC3 and PCDHGA7 in HCT116
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methylated (M) and unmethylated (UM) DNA fragments; presence
or absence of restriction enzyme is indicated (+/2).
Found at: doi:10.1371/journal.pgen.1000745.s006 (1.25 MB TIF)
Figure S7 Suppression of colony formation is not dependent on
non-specific toxicity of transfected genes. Mutant b-catenin (Y33,
tyrosine at amino-acid 33) expression does not suppress colony
formation in HEK293 cells. HEK293 cells were transfected with
CTNNB1 cDNA cloned in the same expression vector
(pcDNA3.1/Zeo) as PCDH constructs. After selection and staining,
plates were photographed and colony counts determined for each
transfection. Representative plates (above) and mean colony
counts (below) are shown. Verification of b-catenin protein
expression after transfection is shown by immunoblotting below
the histograms, together with tubulin to control loading.
Found at: doi:10.1371/journal.pgen.1000745.s007 (1.35 MB TIF)
Figure S8 Kidneys of heterozygous Pcdhg@ mutant mice show
no malformations (see Text S1). Histology of three-month old
wild-type (wt, n=2) and heterozygous Pcdhg@ mutant kidneys
(het, n=3) was examined on cryosections. Staining of adjacent
sections with cresyl-violet (left column) and nuclear fast red (middle
and right columns) was used to highlight the cytoarchitecture of
the specimens. The overall morphology of the heterozygous
kidneys appeared normal and showed no malformations. Scale
bars =500 mm. At higher magnifications, findings were compa-
rable in three-month old wild-type and heterozygous littermates
and displayed normal cytoarchitecture in aged heterozygous mice
(boxed areas are shown in the right column, scale bars =100 mm).
Found at: doi:10.1371/journal.pgen.1000745.s008 (1.02 MB TIF)
Table S1 Wilms’ tumour hypermethylated genes identified by
MeDIP-chip. Summary table of hypermethylated genes identified
by MeDIP-chip in five Wilms’ tumours (P,0.05). Ensembl gene
ID, gene symbol, and co-ordinates by chromosome and gene start
(HG18 genome build) are given. The frequency of hypermethyla-
tion is given in the final column. Blanks in the Gene name column
represent Refseq unannotated genes.
Found at: doi:10.1371/journal.pgen.1000745.s009 (0.23 MB
XLS)
Table S2 COBRA methylation summary. Methylation data
from normal and tumour samples ascertained by combined
bisulphite restriction analysis (COBRA). U, unmethylated; M,
predominantly methylated; m, partially methylated. L and R,
tumours of the left and right kidneys, respectively.
Found at: doi:10.1371/journal.pgen.1000745.s010 (0.04 MB
XLS)
Table S3 Clinical details of nephrogenic rests and Wilms’
tumours. Age at diagnosis: m, age in months. Histology: FH,
favorable histology; UH, unfavorable histology; TR, triphasic; B,
blastemal predominant; E; epithelial predominant; S, stromal
predominant; A, anaplastic; T, teratoid; R, regressive. Outcome:
A, alive; R, relapsed; D, died. WT1 mutation: Y, yes; N, no. WT1
mutation details: G/L, germline. Blank entry, not done.
Found at: doi:10.1371/journal.pgen.1000745.s011 (0.02 MB
XLS)
Table S4 Oligonucleotide primers used in this study.
Found at: doi:10.1371/journal.pgen.1000745.s012 (0.04 MB
XLS)
Text S1 Supporting information methods.
Found at: doi:10.1371/journal.pgen.1000745.s013 (0.03 MB
DOC)
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